Condition: Sarcoma · Sarcoma,Soft Tissue · Sarcoma of Bone · Sponsor: Ruijin Hospital
The aim of this study is to evaluate the efficacy and safety of PARP Inhibition and programmed cell death protein-1 (PD-1) blockade immunotherapy with concurrent stereotactic body radiotherapy (SBRT) for metastatic or advanced bone and soft tissue sarcoma.
This description comes directly from the study's public registry record.
Weibin Zhang, PhD, MD · +8613501824630 · zhangweibin10368@163.com
Yuhui Shen, PhD, MD · +8613918209875 · yuhuiss@163.com
Always discuss trial participation with your own doctor first.
| Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06074692